Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland
| Autor: | Lucas M. Bachmann, Martin Schmid, Eva Blozik, Roland Rapold, Oliver Reich |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty genetic structures Recombinant Fusion Proteins Population Angiogenesis Inhibitors 03 medical and health sciences Young Adult 0302 clinical medicine Health insurance lcsh:Ophthalmology Internal medicine Ranibizumab Health care medicine Cost analysis Humans 030212 general & internal medicine education Aflibercept Aged Retrospective Studies Aged 80 and over education.field_of_study business.industry Macular degeneration Confounding Claims data General Medicine Health Care Costs Middle Aged medicine.disease Confidence interval Ophthalmology Receptors Vascular Endothelial Growth Factor lcsh:RE1-994 Intravitreal Injections 030221 ophthalmology & optometry Female business Switzerland medicine.drug Research Article |
| Zdroj: | BMC Ophthalmology, Vol 17, Iss 1, Pp 1-8 (2017) BMC Ophthalmology |
| ISSN: | 1471-2415 |
| DOI: | 10.1186/s12886-017-0617-x |
| Popis: | Background Previous analyses of real-life data indicated that injection frequency and health care costs did not differ for anti-VEGF treatment with aflibercept and ranibizumab. The objective of this study was to investigate whether this finding persisted when analysing a longer time period after licensing. Methods Retrospective analysis of health insurance claims data of two large Swiss basic health insurance plans including 28% of the Swiss population. Patients qualified for inclusion if aflibercept or ranibizumab treatment had been initiated between June 1, 2013 and November 1, 2014. Within this set, patients with at least 12 months of continuous insurance enrolment in the previous year, 12-month follow-up, and without change of anti-VEGF drug were considered. We examined the distribution of demographic data and patient characteristics between those receiving ranibizumab and those receiving aflibercept. Numbers of injections and associated health care expenditures observed during the 12-month follow-up period after incident treatment were the two outcomes considered. In multivariate regression analyses, controlling for possible confounding factors, we compared differences in these two outcomes between patients treated with aflibercept as compared to ranibizumab. Results A total of 3′058 patients were analysed, 790 (26%) receiving aflibercept and 2`268 receiving ranibizumab (74%). The use of aflibercept (average number of injections 6.2) as compared to ranibizumab (average number of injections 5.7) in the follow-up period of 1 to 12 months, was associated with a 12% increase in the injection frequency (95% confidence interval (CI) 6–17%; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink